| 19.34 -0.11 (-0.57%) | 06-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 24.08 |
1-year : | 28.13 |
| Resists | First : | 20.62 |
Second : | 24.08 |
| Pivot price | 16.25 |
|||
| Supports | First : | 15.45 |
Second : | 12.26 |
| MAs | MA(5) : | 18.9 |
MA(20) : | 15.84 |
| MA(100) : | 19.95  |
MA(250) : | 17.9 |
|
| MACD | MACD : | 0.2 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 83.7 |
D(3) : | 82.5 |
| RSI | RSI(14): 59.5 |
|||
| 52-week | High : | 29.64 | Low : | 9.97 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ TNDM ] has closed below upper band by 14.5%. Bollinger Bands are 35.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 20.65 - 20.75 | 20.75 - 20.85 |
| Low: | 19.04 - 19.16 | 19.16 - 19.28 |
| Close: | 19.12 - 19.31 | 19.31 - 19.5 |
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Fri, 05 Jun 2026
Tandem Diabetes (TNDM) Secures CE Mark for Expanded Use of Insul - GuruFocus
Fri, 05 Jun 2026
Tandem insulin pumps cleared in EU for expanded indications - Seeking Alpha
Fri, 05 Jun 2026
Tandem Diabetes Care Automated Insulin Delivery Systems Receive CE Mark for Type 2 Diabetes and Type 1 Diabetes During Pregnancy - Business Wire
Thu, 04 Jun 2026
[Form 4] TANDEM DIABETES CARE INC Insider Trading Activity - Stock Titan
Thu, 04 Jun 2026
Reasons to Add Tandem Diabetes Stock to Your Portfolio Right Now - TradingView
Thu, 04 Jun 2026
Tandem: Upgrading To Hold On A High-Stakes Pivot Story - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 69 (M) |
| Shares Float | 63 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 117.8 (%) |
| Shares Short | 10,800 (K) |
| Shares Short P.Month | 9,640 (K) |
| EPS | -1.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.26 |
| Profit Margin | -9.2 % |
| Operating Margin | -7.1 % |
| Return on Assets (ttm) | -3.7 % |
| Return on Equity (ttm) | -65.8 % |
| Qtrly Rev. Growth | 5.5 % |
| Gross Profit (p.s.) | 8.23 |
| Sales Per Share | 15.02 |
| EBITDA (p.s.) | -0.64 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 20 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -14.12 |
| PEG Ratio | 0 |
| Price to Book value | 8.51 |
| Price to Sales | 1.28 |
| Price to Cash Flow | 67.58 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|